Easy-To-Trade Cannabis Stocks: Insights Into How Trading Activity Affects These Investments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2024
0mins
Should l Buy CRON?
Source: Benzinga
- Trading Volume and Liquidity: Trading volume reflects shares bought and sold, impacting liquidity in the stock market.
- High-Liquidity Cannabis Stocks: Examples like SNDL, Tilray Brands, Cronos Group, and Aurora Cannabis show strong liquidity.
- Pros of High-Liquidity Stocks: Reduced transaction costs, flexibility, and market confidence are advantages.
- Cons of High-Liquidity Stocks: Despite benefits, high trading volumes can lead to price volatility.
- Low-Liquidity Cannabis Stocks: Stocks like Medical Marijuana, Trees, Curaleaf Holdings, and Green Thumb Industries have lower liquidity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.510
Low
2.30
Averages
2.72
High
3.14
Current: 2.510
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
Altria Faces Challenges in Tobacco Market
- Stock Performance Review: While Altria has historically achieved an annual return of 20%, its performance over the past decade has been lackluster due to declining smoking rates in the U.S., highlighting the vulnerability of its core business.
- Diversification Failures: Altria's investments in Cronos Group and Juul Labs have resulted in billions in losses, and its recent acquisition of NJOY faced a ban from the U.S. International Trade Commission due to patent infringement, exacerbating financial pressures.
- New Product Sales Growth: Despite the decline in its core business, Altria's On! oral nicotine pouches saw an 11% increase in sales to 177.8 million cans over the past year, but a drop in market share indicates competitive pressures, particularly from Philip Morris's Zyn.
- Future Earnings Outlook: Altria projects earnings per share growth of 2.5% to 5.5%, reaching $5.56 to $5.72 in 2026, and with a 6.3% dividend yield, it still presents some investment appeal despite the risks associated with its declining core business.
See More
Altria's Diversification Efforts Falter
- Core Business Decline: Altria has managed profit growth by raising cigarette prices, yet its 2025 revenue after excise taxes fell 1.5% to $20.1 billion, indicating a persistent decline in its core business and significant risks for future growth.
- New Product Market Competition: Altria's On! oral nicotine pouches saw an 11% shipment increase to 177.8 million cans over the past year, but a decline in market share in Q4 due to Zyn's promotions suggests limited market acceptance for new products.
- Shareholder Returns and Risks: Despite a roughly 50% stock price increase over the past two years, Altria's 2026 earnings per share target of $5.56 to $5.72, combined with a 6.3% dividend yield, highlights the challenges and uncertainties the company faces during its transition.
- Uncertain Industry Outlook: With smoking rates among young Americans continuing to decline, Altria's cigarette sales are almost certain to keep falling, and if the company cannot replace lost profits with new products, its long-term stock price will face downward pressure.
See More
Cronos Group Reports Record Growth in 2025 Earnings Call
- Significant Revenue Growth: Cronos Group reported a consolidated net revenue of $44.5 million for Q4 2025, reflecting a 47% year-over-year increase driven by strong cannabis flower sales in Israel and Canada, underscoring the continued strength of its core business.
- Market Leadership Reinforced: The Spinach brand emerged as the second-largest vape brand in Canada and achieved the top market share in vape cartridges, further solidifying the company's leadership position in the rapidly growing consumer goods market.
- Strategic Acquisition Plans: The company announced a definitive agreement to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for €57.5 million (approximately $67.5 million), with closing expected in H1 2026, which will provide robust support for the company's expansion into the European market.
- Strong Financial Position: Cronos Group maintains the strongest balance sheet in the industry with no debt and $832 million in cash and short-term investments, demonstrating the company's financial flexibility for future expansions and acquisitions.
See More
Cronos Reports Q4 Revenue Beat Despite Net Loss
- Significant Revenue Growth: Cronos reported $44.5 million in revenue for Q4 2025, reflecting approximately 47% year-over-year growth, exceeding market expectations by $5.8 million, primarily driven by improved flower sales in multiple countries, including Israel.
- Gross Profit Increase: The company's gross profit rose nearly 50% year-over-year to $16.2 million, indicating enhanced sales volumes and average selling prices, although overall performance was impacted by foreign currency transaction losses.
- Net Loss Reported: Despite revenue growth, Cronos swung to a net loss of $0.5 million from a net income of $43.9 million in the prior-year period, highlighting the significant impact of foreign exchange losses on the company's financials.
- Annual Financial Overview: For the full year, Cronos posted a net loss of $9.4 million on $146.6 million in revenue, indicating approximately 25% year-over-year growth, while cash and cash equivalents fell about 8% year-over-year to $791.8 million, reflecting financial pressures amid market expansion efforts.
See More
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
Altria Faces Challenges in Tobacco Market
- Stock Performance Review: While Altria has historically achieved an annual return of 20%, its performance over the past decade has been lackluster due to declining smoking rates in the U.S., highlighting the vulnerability of its core business.
- Diversification Failures: Altria's investments in Cronos Group and Juul Labs have resulted in billions in losses, and its recent acquisition of NJOY faced a ban from the U.S. International Trade Commission due to patent infringement, exacerbating financial pressures.
- New Product Sales Growth: Despite the decline in its core business, Altria's On! oral nicotine pouches saw an 11% increase in sales to 177.8 million cans over the past year, but a drop in market share indicates competitive pressures, particularly from Philip Morris's Zyn.
- Future Earnings Outlook: Altria projects earnings per share growth of 2.5% to 5.5%, reaching $5.56 to $5.72 in 2026, and with a 6.3% dividend yield, it still presents some investment appeal despite the risks associated with its declining core business.
See More
Altria's Diversification Efforts Falter
- Core Business Decline: Altria has managed profit growth by raising cigarette prices, yet its 2025 revenue after excise taxes fell 1.5% to $20.1 billion, indicating a persistent decline in its core business and significant risks for future growth.
- New Product Market Competition: Altria's On! oral nicotine pouches saw an 11% shipment increase to 177.8 million cans over the past year, but a decline in market share in Q4 due to Zyn's promotions suggests limited market acceptance for new products.
- Shareholder Returns and Risks: Despite a roughly 50% stock price increase over the past two years, Altria's 2026 earnings per share target of $5.56 to $5.72, combined with a 6.3% dividend yield, highlights the challenges and uncertainties the company faces during its transition.
- Uncertain Industry Outlook: With smoking rates among young Americans continuing to decline, Altria's cigarette sales are almost certain to keep falling, and if the company cannot replace lost profits with new products, its long-term stock price will face downward pressure.
See More
Cronos Group Reports Record Growth in 2025 Earnings Call
- Significant Revenue Growth: Cronos Group reported a consolidated net revenue of $44.5 million for Q4 2025, reflecting a 47% year-over-year increase driven by strong cannabis flower sales in Israel and Canada, underscoring the continued strength of its core business.
- Market Leadership Reinforced: The Spinach brand emerged as the second-largest vape brand in Canada and achieved the top market share in vape cartridges, further solidifying the company's leadership position in the rapidly growing consumer goods market.
- Strategic Acquisition Plans: The company announced a definitive agreement to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for €57.5 million (approximately $67.5 million), with closing expected in H1 2026, which will provide robust support for the company's expansion into the European market.
- Strong Financial Position: Cronos Group maintains the strongest balance sheet in the industry with no debt and $832 million in cash and short-term investments, demonstrating the company's financial flexibility for future expansions and acquisitions.
See More
Cronos Reports Q4 Revenue Beat Despite Net Loss
- Significant Revenue Growth: Cronos reported $44.5 million in revenue for Q4 2025, reflecting approximately 47% year-over-year growth, exceeding market expectations by $5.8 million, primarily driven by improved flower sales in multiple countries, including Israel.
- Gross Profit Increase: The company's gross profit rose nearly 50% year-over-year to $16.2 million, indicating enhanced sales volumes and average selling prices, although overall performance was impacted by foreign currency transaction losses.
- Net Loss Reported: Despite revenue growth, Cronos swung to a net loss of $0.5 million from a net income of $43.9 million in the prior-year period, highlighting the significant impact of foreign exchange losses on the company's financials.
- Annual Financial Overview: For the full year, Cronos posted a net loss of $9.4 million on $146.6 million in revenue, indicating approximately 25% year-over-year growth, while cash and cash equivalents fell about 8% year-over-year to $791.8 million, reflecting financial pressures amid market expansion efforts.
See More
